PubMed Health⌕ Search

Biomedical subjects

K Mattucci

Publications and source records attributed to K Mattucci.

4 recordsLinked to original sources
PubMed1991

Cochlear implants as a contraindication to magnetic resonance imaging.

Magnetic resonance imaging poses little risk to the majority of patients undergoing scanning. However, cochlear implantation should pose a contraindication to this imaging process. This conclusion is based on several findings of in vitro testing of three cochlear implants: the 3M/House and 3M/Vienna designs and the Nucleus device. Specifically, tremendous torques are generated by each of these devices when they are introduced into the coil of a magnetic resonance imager; in addition, the 3M products not only were noted to induce an electrical current, but also were significantly magnetized and rendered afunctional. The clinical implications are discussed.

Cochlear Implants↗
PubMed1986

Acrofacial dysostosis of Nager and ocular abnormalities.

Acrofacial dysostosis of Nager is a little known hereditary syndrome in which the findings of mandibulofacial dysostosis are associated with defects of the limbs. The present case showed other abnormalities including the Stilling-Turk-Duane syndrome, conductive deafness and ptosis of the transverse colon.

Abnormalities, Multiple↗
PubMed1983

Multi-center, double-blind, placebo-controlled trial of fluocortin butyl in perennial rhinitis.

Fluocortin butyl (FCB) is a newly synthesized corticosteroid with a high ratio of topical to systemic activity. FCB was studied in a multi-center, double-blind, placebo-controlled trial of therapy of perennial rhinitis. The study was conducted between January and May 1981. Patients evaluated suffered from either chronic allergic or chronic nonallergic rhinitis or both. A total of 306 patients from 16 investigative centers were evaluated by comparing FCB to placebo. Three separate dosage regimens were employed. Patients received a total daily dose of 2, 4, or 8 mg. FCB was found to be an effective therapeutic agent. It reduced symptoms of nasal congestion, rhinorrhea, postnasal drainage, and sneezing. It also markedly reduced the use of concomitant medications (chlorpheniramine maleate and/or pseudoephedrine). Relief of symptoms was noted as early as the first week of therapy, and the degree of improvement increased progressively during the study. There was little difference between the relief produced by the 4 mg and 8 mg regimens. Both of these were superior to the 2 mg regimen. The drug was well tolerated; no significant side effects were noted.

Adult↗